The angiogenic properties of human amniotic membrane stem cells are enhanced in gestational diabetes and associate with fetal adiposity.


Journal

Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581

Informations de publication

Date de publication:
20 12 2021
Historique:
received: 22 03 2021
accepted: 09 12 2021
entrez: 21 12 2021
pubmed: 22 12 2021
medline: 24 3 2022
Statut: epublish

Résumé

An environment of gestational diabetes mellitus (GDM) can modify the phenotype of stem cell populations differentially according to their placental localization, which can be useful to study the consequences for the fetus. We sought to explore the effect of intrauterine GDM exposure on the angiogenic properties of human amniotic membrane stem cells (hAMSCs). We comprehensively characterized the angiogenic phenotype of hAMSCs isolated from 14 patients with GDM and 14 controls with normal glucose tolerance (NGT). Maternal and fetal parameters were also recorded. Hyperglycemia, hyperinsulinemia and palmitic acid were used to in vitro mimic a GDM-like pathology. Pharmacological and genetic inhibition of protein function was used to investigate the molecular pathways underlying the angiogenic properties of hAMSCs isolated from women with GDM. Capillary tube formation assays revealed that GDM-hAMSCs produced a significantly higher number of nodes (P = 0.004), junctions (P = 0.002) and meshes (P < 0.001) than equivalent NGT-hAMSCs, concomitant with an increase in the gene/protein expression of FGFR2, TGFBR1, SERPINE1 and VEGFA. These latter changes were recapitulated in NGT-hAMSCs exposed to GDM-like conditions. Inhibition of the protein product of SERPINE1 (plasminogen activator inhibitor 1, PAI-1) suppressed the angiogenic properties of GDM-hAMSCs. Correlation analyses revealed that cord blood insulin levels in offspring strongly correlated with the number of nodes (r = 0.860; P = 0.001), junctions (r = 0.853; P = 0.002) and meshes (r = 0.816; P = 0.004) in tube formation assays. Finally, FGFR2 levels correlated positively with placental weight (r = 0.586; P = 0.028) and neonatal adiposity (r = 0.496; P = 0.014). GDM exposure contributes to the angiogenic abilities of hAMSCs, which are further related to increased cord blood insulin and fetal adiposity. PAI-1 emerges as a potential key player of GDM-induced angiogenesis.

Sections du résumé

BACKGROUND
An environment of gestational diabetes mellitus (GDM) can modify the phenotype of stem cell populations differentially according to their placental localization, which can be useful to study the consequences for the fetus. We sought to explore the effect of intrauterine GDM exposure on the angiogenic properties of human amniotic membrane stem cells (hAMSCs).
METHODS
We comprehensively characterized the angiogenic phenotype of hAMSCs isolated from 14 patients with GDM and 14 controls with normal glucose tolerance (NGT). Maternal and fetal parameters were also recorded. Hyperglycemia, hyperinsulinemia and palmitic acid were used to in vitro mimic a GDM-like pathology. Pharmacological and genetic inhibition of protein function was used to investigate the molecular pathways underlying the angiogenic properties of hAMSCs isolated from women with GDM.
RESULTS
Capillary tube formation assays revealed that GDM-hAMSCs produced a significantly higher number of nodes (P = 0.004), junctions (P = 0.002) and meshes (P < 0.001) than equivalent NGT-hAMSCs, concomitant with an increase in the gene/protein expression of FGFR2, TGFBR1, SERPINE1 and VEGFA. These latter changes were recapitulated in NGT-hAMSCs exposed to GDM-like conditions. Inhibition of the protein product of SERPINE1 (plasminogen activator inhibitor 1, PAI-1) suppressed the angiogenic properties of GDM-hAMSCs. Correlation analyses revealed that cord blood insulin levels in offspring strongly correlated with the number of nodes (r = 0.860; P = 0.001), junctions (r = 0.853; P = 0.002) and meshes (r = 0.816; P = 0.004) in tube formation assays. Finally, FGFR2 levels correlated positively with placental weight (r = 0.586; P = 0.028) and neonatal adiposity (r = 0.496; P = 0.014).
CONCLUSIONS
GDM exposure contributes to the angiogenic abilities of hAMSCs, which are further related to increased cord blood insulin and fetal adiposity. PAI-1 emerges as a potential key player of GDM-induced angiogenesis.

Identifiants

pubmed: 34930438
doi: 10.1186/s13287-021-02678-y
pii: 10.1186/s13287-021-02678-y
pmc: PMC8691045
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

608

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2021. The Author(s).

Références

Entringer S, Buss C, Swanson JM, Cooper DM, Wing DA, Waffarn F, et al. Fetal programming of body composition, obesity, and metabolic function: the role of intrauterine stress and stress biology. J Nutr Metab. 2012;2012:16. https://doi.org/10.1155/2012/632548 .
doi: 10.1155/2012/632548
Lindsay KL, Buss C, Wadhwa PD, Entringer S. The Interplay between maternal nutrition and stress during pregnancy: issues and considerations. Ann Nutr Metab. 2017;70:191–200. https://doi.org/10.1159/000457136 .
doi: 10.1159/000457136 pubmed: 28301838
Hanson MA, Gluckman PD. Early developmental conditioning of later health and disease: Physiology or pathophysiology? Physiol Rev. 2014;94:1027–76. https://doi.org/10.1152/physrev.00029.2013 .
doi: 10.1152/physrev.00029.2013 pubmed: 25287859 pmcid: 4187033
Whitaker RC, Pepe MS, Seidel KD, Wright JA, Knopp RH. Gestational diabetes and the risk of offspring obesity. Pediatrics. 1998;101:E9.
doi: 10.1542/peds.101.2.e9 pubmed: 9445519
Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care. 2002;25:1862–8. https://doi.org/10.2337/diacare.25.10.1862 .
doi: 10.2337/diacare.25.10.1862 pubmed: 12351492
Carr DB, Utzschneider KM, Hull RL, Tong J, Wallace TM, Kodama K, et al. Gestational diabetes mellitus increases the risk of cardiovascular disease in women with a family history of type 2 diabetes. Diabetes Care. 2006;29:2078–83. https://doi.org/10.2337/DC05-2482 .
doi: 10.2337/DC05-2482 pubmed: 16936156
Jones HN, Powell TL, Jansson T. Regulation of placental nutrient transport—a review. Placenta. 2007;28:763–74. https://doi.org/10.1016/j.placenta.2007.05.002 .
doi: 10.1016/j.placenta.2007.05.002 pubmed: 17582493
Chen L, Merkhan MM, Forsyth NR, Wu P. Chorionic and amniotic membrane-derived stem cells have distinct, and gestational diabetes mellitus independent, proliferative, differentiation, and immunomodulatory capacities. Stem Cell Res. 2019;40: 101537. https://doi.org/10.1016/j.scr.2019.101537 .
doi: 10.1016/j.scr.2019.101537 pubmed: 31422237
Wajid N, Naseem R, Anwar SS, Awan SJ, Ali M, Javed S, et al. The effect of gestational diabetes on proliferation capacity and viability of human umbilical cord-derived stromal cells. Cell Tissue Bank. 2015;16:389–97. https://doi.org/10.1007/s10561-014-9483-4 .
doi: 10.1007/s10561-014-9483-4 pubmed: 25407535
Chen L, Forsyth NR, Wu P. Chorionic and amniotic placental membrane-derived stem cells, from gestational diabetic women, have distinct insulin secreting cell differentiation capacities. J Tissue Eng Regen Med. 2020;14:243–56. https://doi.org/10.1002/term.2988 .
doi: 10.1002/term.2988 pubmed: 31701635
Kong CM, Subramanian A, Biswas A, Stunkel W, Chong YS, Bongso A, et al. Changes in stemness properties, differentiation potential, oxidative stress, senescence and mitochondrial function in wharton’s jelly stem cells of umbilical cords of mothers with gestational diabetes mellitus. Stem Cell Rev Reports. 2019;15:415–26. https://doi.org/10.1007/s12015-019-9872-y .
doi: 10.1007/s12015-019-9872-y
Chen L, Wang CT, Forsyth NR, Wu P. Transcriptional profiling reveals altered biological characteristics of chorionic stem cells from women with gestational diabetes. Stem Cell Res Ther. 2020;11:1–15. https://doi.org/10.1186/s13287-020-01828-y .
doi: 10.1186/s13287-020-01828-y
Kim J, Piao Y, Pak YK, Chung D, Han YM, Hong JS, et al. Umbilical cord mesenchymal stromal cells affected by gestational diabetes mellitus display premature aging and mitochondrial dysfunction. Stem Cells Dev. 2015;24:575–86. https://doi.org/10.1089/scd.2014.0349 .
doi: 10.1089/scd.2014.0349 pubmed: 25437179
Algaba-Chueca F, Maymó-Masip E, Ejarque M, Ballesteros M, Llauradó G, López C, et al. Gestational diabetes impacts fetal precursor cell responses with potential consequences for offspring. Stem Cells Transl Med. 2020;9:351–63. https://doi.org/10.1002/sctm.19-0242 .
doi: 10.1002/sctm.19-0242 pubmed: 31880859
Zhang C, Yu L, Liu S, Wang Y. Human amnion-derived mesenchymal stem cells promote osteogenic and angiogenic differentiation of human adipose-derived stem cells. PLoS ONE. 2017;12: e0186253. https://doi.org/10.1371/journal.pone.0186253 .
doi: 10.1371/journal.pone.0186253 pubmed: 29020045 pmcid: 5636128
Jiang F, Ma J, Liang Y, Niu Y, Chen N, Shen M. Amniotic mesenchymal stem cells can enhance angiogenic capacity via MMPs in vitro and in vivo. Biomed Res Int. 2015;2015: 324014. https://doi.org/10.1155/2015/324014 .
doi: 10.1155/2015/324014 pubmed: 26491665 pmcid: 4600487
Wu Q, Fang T, Lang H, Chen M, Shi P, Pang X, et al. Comparison of the proliferation, migration and angiogenic properties of human amniotic epithelial and mesenchymal stem cells and their effects on endothelial cells. Int J Mol Med. 2017;39:918–26. https://doi.org/10.3892/ijmm.2017.2897 .
doi: 10.3892/ijmm.2017.2897 pubmed: 28259958 pmcid: 5360425
Kim SW, Zhang HZ, Kim CE, An HS, Kim JM, Kim MH. Amniotic mesenchymal stem cells have robust angiogenic properties and are effective in treating hindlimb ischaemia. Cardiovasc Res. 2012;93:525–34. https://doi.org/10.1093/cvr/cvr328 .
doi: 10.1093/cvr/cvr328 pubmed: 22155484
König J, Huppertz B, Desoye G, Parolini O, Fröhlich JD, Weiss G, et al. Amnion-derived mesenchymal stromal cells show angiogenic properties but resist differentiation into mature endothelial cells. Stem Cells Dev. 2012;21:1309–20. https://doi.org/10.1089/scd.2011.0223 .
doi: 10.1089/scd.2011.0223 pubmed: 21762016
Danieli P, Malpasso G, Ciuffreda MC, Cervio E, Calvillo L, Copes F, et al. Conditioned medium from human amniotic mesenchymal stromal cells limits infarct size and enhances angiogenesis. Stem Cells Transl Med. 2015;4:448–58. https://doi.org/10.5966/sctm.2014-0253 .
doi: 10.5966/sctm.2014-0253 pubmed: 25824141 pmcid: 4414224
Abbasi-Kangevari M, Ghamari SH, Safaeinejad F, Bahrami S, Niknejad H. Potential therapeutic features of human amniotic mesenchymal stem cells in multiple sclerosis: Immunomodulation, inflammation suppression, angiogenesis promotion, oxidative stress inhibition, neurogenesis induction, MMPs regulation, and remyelination stimulation. Front Immunol. 2019;10:238. https://doi.org/10.3389/fimmu.2019.00238 .
doi: 10.3389/fimmu.2019.00238 pubmed: 30842772 pmcid: 6391358
Kim SW, Zhang HZ, Guo L, Kim JM, Kim MH. Amniotic mesenchymal stem cells enhance wound healing in diabetic NOD/SCID mice through high angiogenic and engraftment capabilities. PLoS ONE. 2012. https://doi.org/10.1371/journal.pone.0041105 .
doi: 10.1371/journal.pone.0041105 pubmed: 23300932 pmcid: 3534088
Zhang C, Du Y, Yuan H, Jiang F, Shen M, Wang Y, et al. HAMSCs/HBMSCs coculture system ameliorates osteogenesis and angiogenesis against glucolipotoxicity. Biochimie. 2018;152:121–33. https://doi.org/10.1016/j.biochi.2018.06.028 .
doi: 10.1016/j.biochi.2018.06.028 pubmed: 30103897
Onat D, Brillon D, Colombo PC, Schmidt AM. Human vascular endothelial cells: a model system for studying vascular inflammation in diabetes and atherosclerosis. Curr Diab Rep. 2011;11:193–202. https://doi.org/10.1007/s11892-011-0182-2 .
doi: 10.1007/s11892-011-0182-2 pubmed: 21337131 pmcid: 3311155
Amrithraj AI, Kodali A, Nguyen L, Teo AKK, Chang CW, Karnani N, et al. Gestational diabetes alters functions in offspring’s umbilical cord cells with implications for cardiovascular health. Endocrinology. 2017;158:2102–12. https://doi.org/10.1210/en.2016-1889 .
doi: 10.1210/en.2016-1889 pubmed: 28431037
Grupo Español de Diabetes y Embarazo (GEDE), Grupo Español de Diabetes y Embarazo. Asistencia a la gestante con diabetes. Guía de práctica clínica actualizada en 2014 | Avances en Diabetología. Av en Diabetol 2015;31:45–59. https://doi.org/10.1016/j.avdiab.2014.12.001
National Diabetes Data Group, Group NDD. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1999;28:1039–57.
Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini FC, Krause DS, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315–7. https://doi.org/10.1080/14653240600855905 .
doi: 10.1080/14653240600855905 pubmed: 16923606
Carpentier G, Berndt S, Ferratge S, Rasband W, Cuendet M, Uzan G, et al. Angiogenesis analyzer for ImageJ—a comparative morphometric analysis of “Endothelial Tube Formation Assay” and “Fibrin Bead Assay.” Sci Rep. 2020;10:11568. https://doi.org/10.1038/s41598-020-67289-8 .
doi: 10.1038/s41598-020-67289-8 pubmed: 32665552 pmcid: 7360583
Mathew SA, Naik C, Cahill PA, Bhonde RR. Placental mesenchymal stromal cells as an alternative tool for therapeutic angiogenesis. Cell Mol Life Sci. 2020;77:253–65. https://doi.org/10.1007/s00018-019-03268-1 .
doi: 10.1007/s00018-019-03268-1 pubmed: 31468060
Mamede AC, Carvalho MJ, Abrantes AM, Laranjo M, Maia CJ, Botelho MF. Amniotic membrane: from structure and functions to clinical applications. Cell Tissue Res. 2012;349:447–58. https://doi.org/10.1007/s00441-012-1424-6 .
doi: 10.1007/s00441-012-1424-6 pubmed: 22592624
Liu Q-W, Huang Q-M, Wu H-Y, Zuo G-S-L, Gu H-C, Deng K-Y, et al. Characteristics and therapeutic potential of human amnion-derived stem cells. Int J Mol Sci 2019. https://doi.org/10.3390/ijms22020970
Alviano F, Fossati V, Marchionni C, Arpinati M, Bonsi L, Franchina M, et al. Term amniotic membrane is a high throughput source for multipotent mesenchymal stem cells with the ability to differentiate into endothelial cells in vitro. BMC Dev Biol. 2007;7:11. https://doi.org/10.1186/1471-213X-7-11 .
doi: 10.1186/1471-213X-7-11 pubmed: 17313666 pmcid: 1810523
Wang Y, Chen X, Yin Y, Li S. Human amnion-derived mesenchymal stem cells induced osteogenesis and angiogenesis in human adipose-derived stem cells via ERK1/2 MAPK signaling pathway. BMB Rep. 2018;51:194–9. https://doi.org/10.5483/bmbrep.2018.51.4.005 .
doi: 10.5483/bmbrep.2018.51.4.005 pubmed: 29429450 pmcid: 5933215
Warrier S, Haridas N, Bhonde R. Inherent propensity of amnion-derived mesenchymal stem cells towards endothelial lineage: vascularization from an avascular tissue. Placenta. 2012;33:850–8. https://doi.org/10.1016/j.placenta.2012.07.001 .
doi: 10.1016/j.placenta.2012.07.001 pubmed: 22840296
Nogami M, Tsuno H, Koike C, Okabe M, Yoshida T, Seki S, et al. Isolation and characterization of human amniotic mesenchymal stem cells and their chondrogenic differentiation. Transplantation. 2012;93:1221–8. https://doi.org/10.1097/TP.0b013e3182529b76 .
doi: 10.1097/TP.0b013e3182529b76 pubmed: 23318305
Madazli R, Tuten A, Calay Z, Uzun H, Uludag S, Ocak V. The incidence of placental abnormalities, maternal and cord plasma malondialdehyde and vascular endothelial growth factor levels in women with gestational diabetes mellitus and nondiabetic controls. Gynecol Obstet Invest. 2008;65:227–32. https://doi.org/10.1159/000113045 .
doi: 10.1159/000113045 pubmed: 18196904
Olsson A-K, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling? In control of vascular function. Nat Rev Mol Cell Biol. 2006;7:359–71. https://doi.org/10.1038/nrm1911 .
doi: 10.1038/nrm1911 pubmed: 16633338
Mathew SA, Bhonde R. Mesenchymal stromal cells isolated from gestationally diabetic human placenta exhibit insulin resistance, decreased clonogenicity and angiogenesis. Placenta. 2017;59:1–8. https://doi.org/10.1016/j.placenta.2017.09.002 .
doi: 10.1016/j.placenta.2017.09.002 pubmed: 29108631
Zhou J, Ni X, Huang X, Yao J, He Q, Wang K, et al. Potential role of hyperglycemia in fetoplacental endothelial dysfunction in gestational diabetes mellitus. Cell Physiol Biochem. 2016;39:1317–28. https://doi.org/10.1159/000447836 .
doi: 10.1159/000447836 pubmed: 27606810
Lassance L, Miedl H, Absenger M, Diaz-Perez F, Lang U, Desoye G, et al. Hyperinsulinemia stimulates angiogenesis of human fetoplacental endothelial cells: a possible role of insulin in placental hypervascularization in diabetes mellitus. J Clin Endocrinol Metab. 2013;98:1438–47. https://doi.org/10.1210/jc.2013-1210 .
doi: 10.1210/jc.2013-1210
Chang SC, Vivian Yang WC. Hyperglycemia induces altered expressions of angiogenesis associated molecules in the trophoblast. Evid Based Complement Altern Med. 2013. https://doi.org/10.1155/2013/457971 .
doi: 10.1155/2013/457971
Feng L, Liao WX, Luo Q, Zhang HH, Wang W, Zheng J, et al. Caveolin-1 orchestrates fibroblast growth factor 2 signaling control of angiogenesis in placental artery endothelial cell caveolae. J Cell Physiol. 2012;227:2480–91. https://doi.org/10.1002/jcp.22984 .
doi: 10.1002/jcp.22984 pubmed: 21830216 pmcid: 3248968
Guerrero PA, McCarty JH. TGF-β activation and signaling in angiogenesis. Physiol Pathol Angiogenes Signal Mech Target Ther. 2017. https://doi.org/10.5772/66405 .
doi: 10.5772/66405
Meng Q, Shao L, Luo X, Mu Y, Xu W, Gao L, et al. Expressions of VEGF-A and VEGFR-2 in placentae from GDM pregnancies. Reprod Biol Endocrinol. 2016;14:61. https://doi.org/10.1186/s12958-016-0191-8 .
doi: 10.1186/s12958-016-0191-8 pubmed: 27645229 pmcid: 5029036
Pietro L, Daher S, Rudge MVC, Calderon IMP, Damasceno DC, Sinzato YK, et al. Vascular endothelial growth factor (VEGF) and VEGF-receptor expression in placenta of hyperglycemic pregnant women. Placenta. 2010;31:770–80. https://doi.org/10.1016/j.placenta.2010.07.003 .
doi: 10.1016/j.placenta.2010.07.003 pubmed: 20674013
Orlova VV, Liu Z, Goumans MJ, ten Dijke P. Controlling angiogenesis by two unique TGF-β type I receptor signaling pathways. Histol Histopathol 2011;26:1219–30. https://doi.org/10.14670/HH-26.1219 .
Wu L, Derynck R. Essential role of TGF-β signaling in glucose-induced cell hypertrophy. Dev Cell. 2009;17:35–48. https://doi.org/10.1016/j.devcel.2009.05.010 .
doi: 10.1016/j.devcel.2009.05.010 pubmed: 19619490 pmcid: 2722039
Ziyadeh FN, Sharma K, Ericksen M, Wolf G. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-β. J Clin Invest. 1994;93:536–42. https://doi.org/10.1172/JCI117004 .
doi: 10.1172/JCI117004 pubmed: 8113392 pmcid: 293875
Wu J, Strawn TL, Luo M, Wang L, Li R, Ren M, et al. Plasminogen activator inhibitor-1 inhibits angiogenic signaling by uncoupling vascular endothelial growth factor receptor-2-αVβ3 integrin cross talk. Arterioscler Thromb Vasc Biol. 2015;35:111–20. https://doi.org/10.1161/ATVBAHA.114.304554 .
doi: 10.1161/ATVBAHA.114.304554 pubmed: 25378411
McCann JV, Xiao L, Kim DJ, Khan OF, Kowalski PS, Anderson DG, et al. Endothelial miR-30c suppresses tumor growth via inhibition of TGF-β–induced Serpine1. J Clin Invest. 2019;129:1654–70. https://doi.org/10.1172/JCI123106 .
doi: 10.1172/JCI123106 pubmed: 30855280 pmcid: 6436861
Mehmood S, Ye C, Connelly PW, Hanley AJ, Zinman B, Retnakaran R. Rising plasminogen activator inhibitor-1 and hypoadiponectinemia characterize the cardiometabolic biomarker profile of women with recent gestational diabetes. Cardiovasc Diabetol. 2018;17:133. https://doi.org/10.1186/s12933-018-0776-y .
doi: 10.1186/s12933-018-0776-y pubmed: 30301460 pmcid: 6176527
Tian F-Y, Wang X-M, Xie C, Zhao B, Niu Z, Fan L, et al. Placental surface area mediates the association between FGFR2 methylation in placenta and full-term low birth weight in girls. Clin Epigenetics. 2018;10:39. https://doi.org/10.1186/s13148-018-0472-5 .
doi: 10.1186/s13148-018-0472-5 pubmed: 29588807 pmcid: 5863829
Hill DJ, Tevaarwerk GJ, Caddell C, Arany E, Kilkenny D, Gregory M. Fibroblast growth factor 2 is elevated in term maternal and cord serum and amniotic fluid in pregnancies complicated by diabetes: relationship to fetal and placental size. J Clin Endocrinol Metab. 1995;80:2626–32. https://doi.org/10.1210/jcem.80.9.7673405 .
doi: 10.1210/jcem.80.9.7673405 pubmed: 7673405
Fatimah SS, Tan GC, Chua K, Fariha MMN, Tan AE, Hayati AR. Stemness and angiogenic gene expression changes of serial-passage human amnion mesenchymal cells. Microvasc Res. 2013;86:21–9. https://doi.org/10.1016/j.mvr.2012.12.004 .
doi: 10.1016/j.mvr.2012.12.004 pubmed: 23261754

Auteurs

Sergiy Klid (S)

Rovira i Virgili University, Tarragona, Spain.
CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain.

Francisco Algaba-Chueca (F)

Department of Endocrinology and Nutrition, Research Unit, University Hospital of Tarragona Joan XXIII-Institut d´Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain.
CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain.

Elsa Maymó-Masip (E)

Department of Endocrinology and Nutrition, Research Unit, University Hospital of Tarragona Joan XXIII-Institut d´Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain.
CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain.

Albert Guarque (A)

Rovira i Virgili University, Tarragona, Spain.
CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain.
Department of Obstetrics and Gynecology, University Hospital of Tarragona Joan XXIII, Tarragona, Spain.

Mónica Ballesteros (M)

Rovira i Virgili University, Tarragona, Spain.
CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain.
Department of Obstetrics and Gynecology, University Hospital of Tarragona Joan XXIII, Tarragona, Spain.

Cristina Diaz-Perdigones (C)

Department of Endocrinology and Nutrition, Research Unit, University Hospital of Tarragona Joan XXIII-Institut d´Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain.
CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain.
Department of Obstetrics and Gynecology, University Hospital of Tarragona Joan XXIII, Tarragona, Spain.

Cristina Gutierrez (C)

Rovira i Virgili University, Tarragona, Spain.
Department of Endocrinology and Nutrition, Research Unit, University Hospital of Tarragona Joan XXIII-Institut d´Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain.
CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain.

Joan Vendrell (J)

Rovira i Virgili University, Tarragona, Spain.
Department of Endocrinology and Nutrition, Research Unit, University Hospital of Tarragona Joan XXIII-Institut d´Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain.
CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain.

Ana Megía (A)

Rovira i Virgili University, Tarragona, Spain. ana.megia@gmail.com.
Department of Endocrinology and Nutrition, Research Unit, University Hospital of Tarragona Joan XXIII-Institut d´Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain. ana.megia@gmail.com.
CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain. ana.megia@gmail.com.

Sonia Fernández-Veledo (S)

Department of Endocrinology and Nutrition, Research Unit, University Hospital of Tarragona Joan XXIII-Institut d´Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain. sonia.fernandezveledo@gmail.com.
CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain. sonia.fernandezveledo@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH